Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma.
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500
Informations de publication
Date de publication:
01 11 2021
01 11 2021
Historique:
received:
11
02
2021
revised:
15
05
2021
accepted:
19
08
2021
pubmed:
25
8
2021
medline:
1
4
2022
entrez:
24
8
2021
Statut:
ppublish
Résumé
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas with aggressive clinical behavior. We performed comprehensive miRNA profiling in PTCLs and corresponding normal CD4 We used nCounter (NanoString Inc) for miRNA profiling and validated using Taqman qRT-PCR (Applied Biosystems, Inc). Normal CD4 Effector Th subsets showed distinct miRNA expression with corresponding transcription factor expression (e.g., BCL6/miR-19b, -106, -30d, -26b, in IL21-polarized; GATA3/miR-155, miR-337 in Th2-polarized; and TBX21/miR-181a, -331-3p in Th1-polarized cells). Integration of miRNA signatures suggested activation of TCR and PI3K signaling in IL21-polarized cells, ERK signaling in Th1-polarized cells, and AKT-mTOR signaling in Th2-polarized cells, validated at protein level. In neoplastic counterparts, distinctive miRNAs were identified and confirmed in an independent cohort. Integrative miRNA-mRNA analysis identified a decrease in target transcript abundance leading to deregulation of sphingolipid and Wnt signaling and epigenetic dysregulation in angioimmunoblastic T-cell lymphoma (AITL), while ERK, MAPK, and cell cycle were identified in PTCL subsets, and decreased target transcript abundance was validated in an independent cohort. Elevated expression of miRNAs (miR-126-3p, miR-145-5p) in AITL was associated with poor clinical outcome. Unique miRNAs and deregulated oncogenic pathways are associated with PTCL subtypes. Upregulated miRNA-126-3p and miR-145-5p expression regulate RhoA-GTPase and inhibit T-cell migration, crucial for AITL pathobiology.
Identifiants
pubmed: 34426436
pii: 1078-0432.CCR-21-0573
doi: 10.1158/1078-0432.CCR-21-0573
pmc: PMC8563427
mid: NIHMS1736608
doi:
Substances chimiques
MicroRNAs
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6039-6053Subventions
Organisme : NCI NIH HHS
ID : U01 CA253218
Pays : United States
Organisme : NCI NIH HHS
ID : UH3 CA206127
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA229100
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA251412
Pays : United States
Organisme : NCI NIH HHS
ID : P50 CA136411
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009476
Pays : United States
Organisme : NCI NIH HHS
ID : UH2 CA206127
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA157581
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA036727
Pays : United States
Informations de copyright
©2021 American Association for Cancer Research.
Références
Ann Oncol. 2002 Jan;13(1):140-9
pubmed: 11863096
Gastroenterology. 2002 Jul;123(1):196-205
pubmed: 12105848
Leukemia. 2016 May;30(5):1062-70
pubmed: 26719098
J Exp Med. 2000 Dec 4;192(11):1545-52
pubmed: 11104797
Blood Rev. 2016 Mar;30(2):89-100
pubmed: 26319391
Nat Immunol. 2013 Aug;14(8):840-8
pubmed: 23812098
PLoS One. 2016 Sep 20;11(9):e0163125
pubmed: 27649415
Clin Exp Immunol. 2018 Feb;191(2):166-179
pubmed: 28987000
Blood Cancer J. 2014 Nov 07;4:259
pubmed: 25382608
Blood. 2010 Feb 4;115(5):1026-36
pubmed: 19965671
Immunity. 1998 Nov;9(5):745-55
pubmed: 9846495
J Exp Med. 2005 Oct 17;202(8):1037-42
pubmed: 16230473
Blood. 2013 Sep 19;122(12):2083-92
pubmed: 23801630
J Immunol. 2013 Oct 15;191(8):3973-9
pubmed: 24098055
Immunity. 2005 Oct;23(4):431-43
pubmed: 16226508
Haematologica. 2014 Jan;99(1):116-24
pubmed: 23975180
Immunol Rev. 2019 Mar;288(1):97-111
pubmed: 30874343
Blood. 2015 Oct 8;126(15):1741-52
pubmed: 26268241
Nat Commun. 2015 Mar 06;6:6436
pubmed: 25743066
Blood. 2009 Apr 16;113(16):3754-64
pubmed: 19047678
Nat Genet. 2014 Feb;46(2):166-70
pubmed: 24413734
J Clin Oncol. 2008 Sep 1;26(25):4124-30
pubmed: 18626005
Mol Immunol. 2009 Feb;46(5):999-1006
pubmed: 18990450
Int J Mol Sci. 2016 Oct 13;17(10):
pubmed: 27754357
Blood. 2015 Feb 12;125(7):1137-45
pubmed: 25498913
J Exp Med. 2000 Dec 4;192(11):1553-62
pubmed: 11104798
Immunity. 2011 Dec 23;35(6):919-31
pubmed: 22195747
Nat Immunol. 2011 Jun 05;12(7):672-80
pubmed: 21642988
Nat Rev Immunol. 2013 Sep;13(9):666-78
pubmed: 23907446
Methods Mol Biol. 2019;1960:75-84
pubmed: 30798522
Blood. 2014 May 1;123(18):2893-4
pubmed: 24786457
Int J Mol Sci. 2019 Apr 01;20(7):
pubmed: 30939861
Cancer Biol Med. 2017 Feb;14(1):90-99
pubmed: 28443208
Blood. 2011 Nov 24;118(22):5891-900
pubmed: 21865341
Eur J Immunol. 2010 Jan;40(1):225-31
pubmed: 19877012
Immunity. 2015 Feb 17;42(2):252-264
pubmed: 25692701
Blood. 2003 Feb 1;101(3):815-21
pubmed: 12393412
Blood. 2012 Feb 23;119(8):1901-3
pubmed: 22215888
Anesthesiology. 2015 Aug;123(2):409-22
pubmed: 26200183
Anticancer Res. 2015 Apr;35(4):2055-61
pubmed: 25862860
Front Biosci (Schol Ed). 2015 Jun 01;7:217-25
pubmed: 25961697
J Exp Med. 2015 Feb 9;212(2):217-33
pubmed: 25646266
Blood. 2014 May 8;123(19):2915-23
pubmed: 24632715
Leukemia. 2013 Oct;27(10):2107-11
pubmed: 23594704
Proc Natl Acad Sci U S A. 2010 Sep 14;107(37):16228-33
pubmed: 20805506
Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1024-9
pubmed: 9927687
Blood. 2007 Jun 1;109(11):4952-63
pubmed: 17284527
J Immunol. 2012 Jul 15;189(2):721-31
pubmed: 22675204
Blood Cancer J. 2014 May 30;4:e214
pubmed: 24879115
Blood. 2019 Apr 11;133(15):1664-1676
pubmed: 30782609
Nat Immunol. 2011 Jun 26;12(8):796-803
pubmed: 21706005
Arterioscler Thromb Vasc Biol. 2010 Sep;30(9):1779-86
pubmed: 20702813
J Cell Mol Med. 2013 Feb;17(2):252-64
pubmed: 23301798
Cytokine. 2009 Sep;47(3):149-56
pubmed: 19648026
Lab Invest. 2009 Jun;89(6):708-16
pubmed: 19349957
Cancer Biomark. 2017;18(4):339-347
pubmed: 28128734
J Cell Biol. 2018 Feb 5;217(2):447-457
pubmed: 29233866
Mol Immunol. 2002 Dec;39(9):531-6
pubmed: 12431386
Genomics Proteomics Bioinformatics. 2009 Dec;7(4):147-54
pubmed: 20172487
Blood. 2012 May 24;119(21):4939-48
pubmed: 22490335
Haematologica. 2015 Dec;100(12):e505-7
pubmed: 26405154
Nat Rev Mol Cell Biol. 2020 Oct;21(10):607-632
pubmed: 32576977
Nucleic Acids Res. 2020 Jul 2;48(W1):W521-W528
pubmed: 32374865
Curr Hematol Malig Rep. 2018 Aug;13(4):318-328
pubmed: 29951889
Proc Natl Acad Sci U S A. 2009 Nov 3;106(44):18704-9
pubmed: 19843690
Mol Med Rep. 2014 May;9(5):1877-82
pubmed: 24573110
Trends Immunol. 2013 May;34(5):200-7
pubmed: 23395212
Cell Rep. 2020 Mar 17;30(11):3793-3805.e5
pubmed: 32187550
Immunity. 2013 Jan 24;38(1):13-25
pubmed: 23352221
Blood. 2016 Sep 15;128(11):1490-502
pubmed: 27369867
J Exp Med. 2014 Jun 30;211(7):1297-305
pubmed: 24913235
Blood. 2019 Dec 12;134(24):2159-2170
pubmed: 31562134
Cancer Res. 2007 Nov 15;67(22):10703-10
pubmed: 18006812
FASEB J. 2012 May;26(5):1934-45
pubmed: 22262639
Leukemia. 2011 Dec;25(12):1882-90
pubmed: 21778999
Immunity. 2014 Oct 16;41(4):605-19
pubmed: 25367574
Am J Pathol. 2002 Dec;161(6):1961-71
pubmed: 12466110
Arthritis Rheum. 2011 May;63(5):1376-86
pubmed: 21538319
Blood. 2009 May 7;113(19):4586-94
pubmed: 19202128
BMC Mol Biol. 2006 Jan 31;7:3
pubmed: 16448564
Int Arch Allergy Immunol. 2018;177(3):207-218
pubmed: 30048989